Neurosoft Bioelectronics secures funds to validate its brain implant

Neurosoft Bioelectronics was co-founded in 2020 by Nicolas Vachicouras (CEO), Ludovic Serex (COO), Florian Fallegger (CTO), and Stéphanie Lacour (scientific advisor) who are dedicated to transforming the future of implantable electrical interfaces. Neural implants can be used to diagnose and treat neurological diseases by recording or electrically stimulating neural tissues. However, the long-term success of current neural interfaces is limited by the mechanical mismatch between stiff electronics and soft living tissues. This mismatch causes poor contact between the implant and the underlying tissue and leads to incorrect stimulation, inaccurate recordings, and scarring. 

Neurosoft's neural implants are made of soft materials. Its implants can seamlessly interface with the nervous system, promoting the long-term bio-integration of the devices in the body. Its soft electrodes can be folded into regions of the brain that would otherwise be impossible to access surgically without damaging blood vessels and causing severe complications. The SOFT ECoG, Neurosoft Bioelectronics’ first product, is a brain implant used to monitor drug-resistant epilepsy patients or to guide surgical resection of brain tumours. 

Neurosoft’s technology platform addresses the multi-billion-dollar market of brain-computer interfaces and provides therapies for other severe neurological disorders, such as allowing locked-in patients to interact with their environment. The startup will use the CHF 150,000 obtained from Venture Kick to verify and validate the SOFT ECoG, which is the last step before testing the technology in the clinic. The company also works on closing its Series A fundraising round by this summer.

(Press release/RAN)